Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
107.17
(
-1.00%
)
Bitcoin
67,156.41
(
1.82%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ThomasS

Send PM Follow Ignore
Followers 12
Posts 2277
Boards Moderated 0
Alias Born 05/05/2005

ThomasS

Re: Jonathan Robinson post# 56715

Thursday, 12/27/2007 1:26:32 AM

Thursday, December 27, 2007 1:26:32 AM

Post# of 257302
MNTA: There are clearly several different possibilities to include FDA rejection of Teva/Amphastar's ANDA's at the same time as an approval for MNTA.
Bottom line: If MNTA gets approval for M-Enoxaparin, any subsequent event timing regarding marketing will pale in comparison to the right to market the generic in the first place. Win-win any way we spin it.
Let's just get the approval and go from there, since there are currently too many variables.

"Illegitimacy is something we should talk about in terms of not having it."

- Dan Quayle

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today